Format

Send to

Choose Destination
Best Pract Res Clin Haematol. 2015 Dec;28(4):269-72. doi: 10.1016/j.beha.2015.10.015. Epub 2015 Oct 21.

Hairy cell leukemia: Past, present and future.

Author information

1
Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10065, USA. Electronic address: gettab@mskcc.org.
2
Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10065, USA; Weill Cornell Medical College, 1305 York Avenue, New York 10021, USA. Electronic address: parkj6@mskcc.org.
3
Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York 10065, USA; Weill Cornell Medical College, 1305 York Avenue, New York 10021, USA. Electronic address: TallmanM@mskcc.org.

Abstract

This brief review highlights the sequence of therapeutic milestones and advances in our understanding of the biology of hairy cell leukemia (HCL) with a focus on recent molecular findings and how these may be applied to improve disease outcomes in the future. Targeted therapy is discussed in the context of the recently identified BRAF mutation and other genetic findings.

KEYWORDS:

BRAF; Hairy cell leukemia; Vemurafenib

PMID:
26614906
PMCID:
PMC5008915
DOI:
10.1016/j.beha.2015.10.015
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center